KEI comments on NIH proposed exclusive license to Neogene Therapeutics CRISPR-Engineered T Cell Therapies for the Treatment of Cancer

November 10, 2021 Andrew Burke, Ph.D. Senior Technology Transfer Manager, NCI Technology Transfer Center, Email: andy.burke@nih.gov. Re: Prospective Grant of an Exclusive Patent License: Development and Commercialization of CRISPR-Engineered T Cell Therapies for the Treatment of Cancer to Neogene Therapeutics… Continue Reading

KEI Comments on NIH Prospective Exclusive License to Gilead for HIV Treatment/Cure

(Update: On November 4, 2021, the NIH provided a response to our comments on the license.) On October 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the ““Prospective Grant of an Exclusive… Continue Reading

US government rights in patents on Molnupiravir, based upon funding of R&D at Emory University

(For more resources, please see our page on molnupiravir.) Molnupiravir, the oral pill that is showing promising results as a potential treatment for covid-19, was invented at Emory University with U.S. government funds. After more than six years of non-clinical… Continue Reading

KEI Comments Regarding NIH Prospective License to Blue Water Vaccines for West Nile Vaccine

On September 27, 2021, Knowledge Ecology International (KEI) submitted the following comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent License: Chimeric Live-Attenuated Vaccine for West Nile Virus (WNV)” (86 FR 50722). The technology… Continue Reading

KEI Comments Regarding NIH Exclusive License to Progeria Research Foundation for Ultra-Rare Disease Treatment

Knowledge Ecology International (KEI) filed comments on July 27, 2021 regarding the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Oligonucleotides Analogues Targeting Human LMNA “lamin A” Gene” (86 FR 36563). The inventions are currently co-owned… Continue Reading

KEI Comments to NIH Regarding Proposed Exclusive License to PTC Therapeutics for Gene Therapy

On July 27, 2021, Knowledge Ecology International (KEI) commented on the “Prospective Grant of an Exclusive Patent License: RP2 AAV-Based Gene Human Therapy for Ocular Diseases and Disorders Including XLRP” (86 FR 36565). The National Institutes of Health (NIH) intends… Continue Reading

KEI Comments Regarding NIH Proposed Exclusive License to Yeda

(Update: The NIH provided the following response on July 30, 2021.) Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health’s (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: High ASS1 Expressing… Continue Reading

KEI Comments to the NIH on Exclusive License of AAV Technology to Children’s Medical Research Institute in Australia

Knowledge Ecology International (KEI) submitted comments on Wednesday July 14, 2021 to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Adeno-Associated Virus Polynucleotides, Polypeptides and Virions” (86 FR 34246). The rights to technology… Continue Reading

KEI and UACT Joint Comments to the NIH Regarding Exclusive License to Syncopation for CAR Therapy

Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) on Friday July 9, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific… Continue Reading

KEI Comments on NIH Exclusive License to Panacea for Gene Therapy

On Friday July 9, 2021, Knowledge Ecology International submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Delivery of a Corrective Glucose-6-Phosphatase-Alpha Gene to Treat Glycogen Storage Disease Type 1a (GSD-Ia)… Continue Reading